Analysts’ Top Healthcare Picks: Regeneron (REGN), Resmed (RMD)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Regeneron (REGN – Research Report), Resmed (RMD – Research Report) and Upstream Bio, Inc. (UPB – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Regeneron (REGN)
Truist Financial analyst Gregory Renza maintained a Buy rating on Regeneron today. The company’s shares closed last Thursday at $749.44.
According to TipRanks.com, Renza is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Regeneron with a $847.06 average price target, a 12.1% upside from current levels. In a report issued on January 22, DBS also maintained a Buy rating on the stock with a $910.00 price target.
See the top stocks recommended by analysts >>
Resmed (RMD)
In a report released today, Anthony Petrone from Mizuho Securities maintained a Buy rating on Resmed, with a price target of $300.00. The company’s shares closed last Thursday at $257.61, close to its 52-week high of $263.05.
According to TipRanks.com, Petrone is a 4-star analyst with an average return of
Resmed has an analyst consensus of Moderate Buy, with a price target consensus of $299.11, which is a 16.4% upside from current levels. In a report released today, TipRanks – xAI also upgraded the stock to Buy with a $287.00 price target.
Upstream Bio, Inc. (UPB)
In a report released today, Matt Phipps from William Blair maintained a Buy rating on Upstream Bio, Inc.. The company’s shares closed last Thursday at $30.94.
According to TipRanks.com, Phipps is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Upstream Bio, Inc. with a $48.80 average price target, which is a 61.1% upside from current levels. In a report issued on January 16, LifeSci Capital also maintained a Buy rating on the stock with a $43.00 price target.
